Posted in | News | Medical Optics

Carl Zeiss Meditec Launches Visalis 100 for Surgical Treatment of Cataracts

Carl Zeiss Meditec successfully launched its new Visalis 100 system for the surgical treatment of cataracts at the most important ophthalmic meeting in India, the AIOC (All India Ophthalmology Congress) - which took place this year in Jaipur from 5 - 8 February. For the first time, the company chose a growth market for the initial presentation of an innovation.

With this new system, Carl Zeiss Meditec is further expanding its extensive offering of innovative solutions for eye surgery. At the same time, Visalis 100 is the first system the medical technology provider is offering that is specifically tailored to the needs of doctors in emerging markets. With this new product, the company is reacting to the continuing high level of demand for eye surgery systems particularly in Asia, but also in other regions. “The response from doctors was outstanding. The resulting demand clearly confirms our strategy to continue focusing our developments on the requirements of our customers in the various regions of the world,” emphasizes Dr. Michael Kaschke, President and CEO of Carl Zeiss Meditec AG.

The new Visalis 100 system enables the surgical removal of the natural, diseased lens from the eye during cataract surgery (phaco-emulsification). On the introduction of the system, customers were particularly impressed by its outstanding ease of use and its carefully matched performance parameters. The Visalis 100 ideally rounds off Carl Zeiss Meditec’s portfolio of innovative solutions for eye surgery. It can now offer doctors and hospitals a full line of products for cataract treatment including diagnostic instruments, surgical microsopes, a phaco system, intraocular lenses and systems for follow-up care – all from a single source.

“Particularly in the current phase of the global economy, we are placing increased emphasis on innovation that is sharply focused on customer requirements. Visalis 100 is a further example of the implementation of this goal. We recognized the importance of the newly industrializing countries for our growth at an early stage. Therefore, it was a logical step for us to introduce Visalis 100 as our own system specially tailored to the needs of these markets and hence make the promise of the ZEISS brand something that people could more actively experience in these markets,” Dr. Michael Kaschke concluded.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.